GENETICS & WOMEN’S HEALTH

BRCAssure® and VistaSeq®
Hereditary Cancer Panel

Providing you and your patients a choice in mutation analysis for Hereditary Cancer Syndromes
Every patient comes from a different background with a unique personal and family medical history. When evaluating a patient for hereditary cancer risk, the better test to choose is one that matches the needs of the patient based on the complete medical history.

**BRCAssure® BRCA1/2 Analysis**

BRCAssure is a comprehensive suite of tests to identify BRCA mutations associated with breast, ovarian, and certain other cancers. Patients with a family history that is specific to a cancer type may benefit from a focused genetic test such as BRCAssure BRCA1/2 analysis.

**Indications for BRCAssure Testing**

Consider BRCAssure testing for your patients if their personal or family history has one of the following indications:

- Breast cancer diagnosed at age 45 or younger
- Ovarian cancer
- Both breast and ovarian cancer
- Two primary breast cancers, the first diagnosed at age 50 or younger
- Male breast cancer
- Triple-negative breast cancer diagnosed ≤60 years of age
- Exocrine Pancreatic cancer
- Metastatic or intraductal prostate cancer
- A previously identified BRCA1 or BRCA2 mutation in the family
- Ashkenazi Jewish ancestry; or a relative with breast, pancreatic, or high-grade prostate cancer
- Two or more relatives with breast cancer, one under age 50
- Three or more relatives with breast cancer at any age

**NCCN® and ACOG recognize the importance of testing for BRCA1 and BRCA2 mutations.**

Complete guidelines may be found at www.nccn.org and www.ACOG.org
The NCCN Guidelines® note that multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.³

VistaSeq® Hereditary Cancer Panels

VistaSeq is a multi-gene assay for genetic mutations known to be associated with an increased risk of developing hereditary cancers. Patients who have personal or family medical histories that include a broad spectrum of cancers may gain a better understanding of their cancer risk by utilizing a multi-gene test like the VistaSeq Hereditary Cancer Panel.

**Indications for VistaSeq testing³**

- When a patient’s personal or family medical history suggests a hereditary cancer syndrome
- When a patient’s personal or family history includes several cancer types or could be explained by more than one hereditary cancer syndrome
- When a patient has tested negative or indeterminate for mutations in a single cancer susceptibility gene but whose personal and/or family history suggests a hereditary predisposition for cancer
- To provide clinicians with an assessment of multiple cancer susceptibility genes in a cost-effective and efficient manner
**VistaSeq® summary of panels and associated genes**

Now with more panel options to provide even greater choice for you and your patients.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Common name or condition</th>
<th>VistaSeq 27 genes</th>
<th>VistaSeq without BRCA 25 genes</th>
<th>VistaSeq Breast 19 genes</th>
<th>VistaSeq High/Mod Risk Breast 9 genes</th>
<th>VistaSeq GYN 11 genes</th>
<th>VistaSeq Breast and GYN 25 genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC*</td>
<td>FAP (familial adenomatous polyposis); adenomatous colon polyps</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ATM*</td>
<td>Ataxia telangiectasia (AT)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>BARD1*</td>
<td>Breast and/or ovarian cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>BMPR1A*</td>
<td>Juvenile polyposis syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>BRCA1*</td>
<td>Breast and ovarian cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>BRCA2*</td>
<td>Breast and ovarian cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>BRIP1*</td>
<td>Fanconi anemia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CDH1*</td>
<td>Hereditary diffuse gastric cancer; lobular breast cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CDK4*</td>
<td>Melanoma; cutaneous malignant melanoma</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CDKN2A*</td>
<td>Melanoma; cutaneous malignant melanoma</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CHEK2*</td>
<td>Breast cancer; colon cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>EPCAM*</td>
<td>Lynch syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>FAM175A*</td>
<td>Breast cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>FANCC*</td>
<td>Fanconi anemia</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MLH1*</td>
<td>Lynch syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MRE11A*</td>
<td>Breast cancer; in AR form - ataxia-telangiectasia-like disorder</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MSH2*</td>
<td>Lynch syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MSH6*</td>
<td>Lynch syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MUTYH*</td>
<td>MAP (MYH-associated polyposis) is AR disease; adenomatous colon polyps</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NBN*</td>
<td>Nijmegen breakage syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NF1*</td>
<td>Neurofibromatosis type 1</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PALB2*</td>
<td>Breast cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PM2*</td>
<td>Lynch syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PRKAR1A*</td>
<td>Carney complex</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PTEN*</td>
<td>Cowden disease; Cowden’s</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>RAD50*</td>
<td>Breast and/or ovarian cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>RAD51C*</td>
<td>Breast and/or ovarian cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>RAD51D*</td>
<td>Ovarian cancer</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>SMAD4*</td>
<td>Juvenile polyposis syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>STK11*</td>
<td>Peutz-Jeghers syndrome</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>TP53*</td>
<td>Li-Fraumeni syndrome; PS3</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

**Broadening Your Patients’ Options**

VistaSeq Hereditary Cancer Panels are designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers.
Labcorp provides expertise to your practice through genetic counseling services tailored to you and your patients.

**Comprehensive Genetic Counseling services for Hereditary Cancer**

As a leading provider of genetic testing and counseling services, Integrated Genetics offers one of the largest national commercial networks of genetic counselors. The genetic counseling services provided by Integrated Genetics support patients, physicians, and other providers in many ways, including identifying genetic risks, explaining appropriate genetic testing options, discussing the implications of test results, and helping patients make thoughtful genetic healthcare decisions.

Integrated Genetics provides nationwide access to genetic counseling expertise through our telegenetic counseling program and provides convenience to patients with online scheduling. Your patients can quickly schedule a genetic counseling appointment at www.integratedgenetics.com/genetic-counseling.

Call **855-GC-CALLS (855-422-2557)** to learn more about our exceptional services or visit www.integratedgenetics.com/genetic-counseling.
Continuity of care, pioneering science, professional service

We provide the scientific expertise you need, and the customer experience patients want.

Rapid results
Samples have a typical turnaround time of three to four weeks after a test arrives at our lab.

Extensive managed care contracts
Help patients maximize their benefits.

Convenient blood draws
We have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit Labcorp.com to find your nearest location.

Women’s health and wellness
Labcorp provides access to a complete women’s health offering featuring a full range of testing and services that support the continuity of care for your patients through a single laboratory.

---

Test/Panel Name | Test No.
--- | ---
BRCAsure® Comprehensive BRCA1/2 Analysis | 485030
BRCAsure® Ashkenazi Jewish Panel | 485097
BRCAsure® BRCA1 Targeted Analysis | 485066
BRCAsure® BRCA2 Targeted Analysis | 485081

**Specimen requirements:**
- 7 mL whole blood lavender-top (EDTA) tube
- 2 mL saliva Oragene®•Dx saliva collection kit

Test/Panel Name | Test No.
--- | ---
VistaSeq® Hereditary Cancer Panel | 481220
VistaSeq® without BRCA1 and BRCA2 genes | 481240
VistaSeq® Breast Cancer Panel | 481319
VistaSeq® High/Moderate Risk Breast Cancer Panel | 481452
VistaSeq® GYN Cancer Panel | 481330
VistaSeq® Breast and GYN Cancer Panel | 481341
Mutation-specific Sequencing | 640/641

**Specimen requirements:**
- 10 mL whole blood lavender-top (EDTA) tube
- 2 mL saliva Oragene®•Dx saliva collection kit

---

References

---

Call Us
Toll-free (within the US) at 800.848.4436

Follow Us
Labcorp.com

Visit Us
3400 Computer Drive
Westborough, Massachusetts 01581

Labcorp is a wholly owned subsidiary of Laboratory Corporation of America® Holdings. ©2021 Laboratory Corporation of America® Holdings All rights reserved. rep-982-v6-0521 | L15623-0521-6